SCHEMBL29212392

SCHEMBL29212392

COC(=O)c1cc([N+](=O)[O-])c(OC)cc1S(=O)(=O)Cl

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ VCAM1 P19320 1/20 0.45
▸ PDGFRB P09619 1/20 0.43
▸ FGFR1 P11362 1/20 0.43
▸ PDGFRA P16234 1/20 0.43
▸ FLT1 P17948 1/20 0.43
▸ FGFR3 P22607 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ ALDH1A1 P00352 7/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ CHEK1 O14757 1/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ LMNA P02545 3/20 0.40
▸ HTT P42858 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31305210 0.82 PDGFRB (0.51) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL7344976 0.82 KDM4E (0.54) ALDH1A1KMT2AMEN1MAPTLMNA
SCHEMBL19682569 0.82 VCAM1 (0.46) VCAM1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL8902175 0.81 CHEK1 (0.51) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL6524012 0.81 TRPV4 (0.47) ALDH1A1TDP1KMT2AMEN1MAPT
SCHEMBL1787152 0.80 LMNA (0.52) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL14993998 0.79 PDGFRB (0.62) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL19682921 0.79 GAA (0.53) ALDH1A1KMT2AMEN1MAPTLMNA
SCHEMBL6474988 0.77 PDGFRB (0.47) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2589956 0.77 LMNA (0.52) PDGFRBFGFR1PDGFRAFLT1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 — — US disclosed
EP-4384510-A1 COMPOUNDS TARGETING MUTANT OF P53 Jacobio Pharmaceuticals Co., Ltd. (CN) 2024-06-19 — — EP disclosed
CN-117813295-A Compounds targeting p53 mutants 北京加科思新药研发有限公司 2024-04-02 — — CN disclosed
WO-2023016434-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 VCAM1 2769/4885PDGFRB 3020/4885FGFR1 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback